Development

Novo Nordisk follows Lilly's oral GLP-1 approval with data showing Wegovy's weight loss advantage

Novo Nordisk (NVO) reported that oral semaglutide 25 mg (Wegovy) produced approximately 3 percentage points more weight loss than orforglipron in a population-adjusted indirect comparison. Novo's release of this data comes days after the FDA approved orforglipron under the brand name Foundayo — a timing that sharpens the competitive stakes in the oral GLP-1 obesity market.

The ORION study is a population-adjusted indirect treatment comparison that drew on data from two Phase III trials — OASIS 4 for oral semaglutide and ATTAIN-1 for orforglipron — in adults with obesity or overweight without diabetes.

The analysis used a simulated treatment comparison for weight loss and a two-stage matching-adjusted indirect comparison for tolerability, adjusting for baseline body weight, glycemic status, and sex. Oral semaglutide 25 mg produced a mean weight loss difference of −3.2 percentage points (95% CI: −5.9, −0.4) versus orforglipron 36 mg under the treatment regimen estimand, and −3.0 percentage points (95% CI: −5.8, −0.3) under the efficacy estimand. On tolerability, orforglipron was associated with approximately four times higher odds of discontinuation due to any adverse event (OR 4.1; 95% CI: 1.3, 13.0) and approximately 14 times higher odds of discontinuation due to gastrointestinal adverse events (OR 13.9; 95% CI: 2.0, 96.0). Novo Nordisk noted that the tolerability estimates should be interpreted with caution given low absolute adverse event counts, and that residual confounding and between-trial protocol differences may affect comparability. No head-to-head trial exists between the two agents.

The GI discontinuation signal, while statistically significant, carries wide confidence intervals — the upper bound of the OR for GI-related stopping reached 96.0 — reflecting the small number of events underlying the estimate. Cross-trial comparisons are limited by population differences, protocol heterogeneity, and the absence of randomization between arms, all of which constrain causal inference.

Both oral semaglutide and orforglipron are GLP-1 receptor agonists, but they differ in molecular class. Semaglutide is a peptide analog requiring co-formulation with the absorption enhancer SNAC and a fasting window of at least 30 minutes before eating. Orforglipron is a non-peptide small molecule that carries no food or water restrictions and can be taken at any time of day. That dosing flexibility was a central argument for Eli Lilly's (LLY) product ahead of its FDA approval, and the ORION data — sponsored by Novo Nordisk — directly contests the tolerability framing that accompanied Foundayo's launch.

The AllSci BriefSystematic R&D and deal news. Daily.

A separate patient preference survey, OPTIC, conducted among 800 US adults with obesity or overweight between October and November 2025, found that 84% of respondents favored a treatment profile resembling oral semaglutide over one resembling orforglipron when presented with hypothetical profiles across seven attributes including efficacy, cardiovascular risk reduction, and dosing instructions. The survey has the limitations inherent to observational, cross-sectional design with hypothetical profiles, and was conducted before either product received its current FDA-approved labeling.

The data are set to be presented at the Obesity Medicine Association's annual conference in San Diego. The oral segment now has two approved options with meaningfully different profiles, and the ORION comparison gives Novo Nordisk a data asset to deploy in that conversation, even as its indirect nature limits how far the conclusions can be pushed.

The semaglutide tablets 25 mg label carries a Boxed Warning for possible thyroid tumors, including medullary thyroid carcinoma, and the drug is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Common adverse events include nausea, diarrhea, vomiting, and constipation — the characteristic GI profile of the GLP-1 class. Novo Nordisk plans to present the full ORION and OPTIC datasets at the Obesity Medicine Association 2026 conference in San Diego.


Spot something wrong? Report an issue with this article